Follow us
MEDIA/PRESS RELEASE
Innovation news
Liste des services
-
AdipoPharma obtient un financement pour lancer les essais cliniques de sa molécule, la première de sa catégorie, pour traiter la résistance à l'insuline
12 Novembre 2024
-
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
12 November 2024
-
AdipoPharma, the adipocyte curing company
08 November 2023
-
La biotech alsacienne AdipoPharma et sa molécule miracle à la conquête de l’Amérique
09 February 2023
-
AdipoPharma boucle un tour de table pour son médicament contre le diabète
24 January 2023
-
French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug
23 January 2023
-
La société biotechnologique française AdipoPharma obtient un financement de série A pour un médicament révolutionnaire contre le diabète
23 January 2023
-
Series A for AdipoPharma to advance drug for ‘root cause of type 2 diabetes’
23 January 2023
-
French biotech company AdipoPharma secures Series A funding for breakthrough diabetes drug
23 January 2023
-
French biotech company AdipoPharma wins Series A funding for breakthrough diabetes drug
23 January 2023
-
La société biotechnologique française AdipoPharma obtient un financement de série A pour un médicament révolutionnaire contre le diabète
23 January 2023
-
New treatment set to benefit 1 in 20 Australians living with diabetes
2 September 2022
-
DIABETES DRUG TO CORRECT METABOLIC ABNORMALITIES
AUG/SEP 2022
-
First-in-Class Synthetic Peptide PATAS Promotes Insulin-Free Glucose Absorption
11 August 2022
-
AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate
5 August 2022
-
New medicine class to treat type 2 diabetes
1 August 2022
-
Towards a New Drug Class in the Treatment of Type 2 Diabetes
1 August 2022
-
Monash University: Towards a New Drug Class in the Treatment of Type 2 Diabetes
22 July 2022
-
Towards a New Drug Class in the Treatment of Type 2 Diabetes
20 July 2022
-
Diabète de type 2 : cibler la résistance à l’insuline plutôt que l’hyperglycémie
19 Juillet 2022
-
To treat insulin resistance
19 July 2022
-
당뇨 치료 신세계 시작? 인슐린 저항성 표적 최초 후보물질 'PATAS'
19 July 2022
-
Diabète de type 2 : cibler la résistance à l’insuline plutôt que l’hyperglycémie
19 Juillet 2022
-
Vers une nouvelle classe de médicament pour traiter le diabète de type 2
18 Juillet 2022
-
Diabetes：一种治疗2型糖尿病的新药
15 July 2022
-
Adipopharma’s First-in-class Candidate – PATAS – Shows Improvement in Whole-body Insulin Resistance and Associated Comorbidities in Vivo
15 July 2022
-
Other news to note for July 14, 2022
14 July 2022
-
Towards a New Drug Class in the Treatment of Type 2 Diabetes
14 July 2022
-
Multinational Research Collab Develops New Peptide Capable of Repairing Metabolic Abnormalities Leading to Type 2 Diabetes, Associated Comorbidities
14 July 2022
-
Diabetes: AdipoPharma’s first-in-class candidate – PATAS – shows improvement in whole-body insulin resistance and associated comorbidities in vivo
13 July 2022
-
Aurobac Therapeutics, Boehringer Ingelheim, Evotec, bioMérieux, Adipopharma, Vincent Marion, IntegraGen, OncoDNA
13 Juillet 2022
-
Towards a new drug class in the treatment of type 2 diabetes
13 July 2022
-
Type 2 diabetes drug restores fat cells glucose management
13 July 2022
-
Vers une nouvelle classe de médicament pour traiter le diabète de type 2
13 Juillet 2022
-
Vers une nouvelle classe de médicament pour traiter le diabète de type 2
13 Juillet 2022
-
Diabetes: AdipoPharma’s first-in-class candidate - PATAS - shows improvement in whole-body insulin resistance and associated comorbidities in vivo
13 July 2022
AdipoPharma SAS
Headquarters
Nextmed, Bâtiment eXplora (Bureau A203)
2 rue Marie Hamm
67000 Strasbourg
France
AdipoPharma SRL
Biopark Gosselies
Belgique
AdipoPharma LLC
US Office Pittsburgh
Pennsylvania, USA
© Copyright AdipoPharma 2024 - Privacy Policy - Legal Notice